Our product pipeline includes a complement SARS-CoV-2 vaccine, a Nipah virus vaccine candidate, a West Nile virus vaccine and a sever fever with thrombocytopenia syndrome virus vaccine in development. In all our vaccines the antigen is displayed on a self-assembling nanoparticle directly encoded by a messenger RNA. This nanoparticle enhances immune response, including long term adaptive cell-mediated immunity. The pursued advantages of our nanoparticle vaccines are longer protection, protection against viral dissemination and associated neuropathology, and reduction of the number of challenges necessary for immunization.
Parallel Tracks
Phylex BioSciences follows parallel tracks for preclinical-grade manufacturing and cGMP manufacturing of our candidate vaccines. This allows the company to move directly into cGMP production after preclinical immunogenicity and protection studies are completed.
Phylex BioSciences uses identical formulation and delivery system for all its mRNA candidate vaccines. The advantages of our formulation and delivery, that differ from currently approved mRNA vaccines, are enhanced immunogenicity, reduced side effects, easier administration and longer shelf life.
Phylex BioSciences is pursuing a mRNA formulation with the objective of eliminating cold chain logistics for our candidate mRNA vaccines.